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The CNS role of Toll-like receptor 4 in innate
neuroimmunity and painful neuropathy
Flobert Y. Tanga*†‡, Nancy Nutile-McMenemy*‡, and Joyce A. DeLeo*†‡§
Departments of *Anesthesiology and §Pharmacology and ‡Neuroscience Center at Dartmouth, Dartmouth Medical School, Lebanon, NH 03756
Communicated by Susan E. Leeman, Boston University School of Medicine, Boston, MA, March 3, 2005 (received for review October 28, 2004)
Neuropathic pain remains a prevalent and persistent clinical prob-
lem because of our incomplete understanding of its pathogenesis.
This study demonstrates for the first time, to our knowledge, a
critical role for CNS innate immunity by means of microglial
Toll-like receptor 4 (TLR4) in the induction phase of behavioral
hypersensitivity in a mouse and rat model of neuropathy. We
hypothesized that after L5 nerve transection, CNS neuroimmune
activation and subsequent cytokine expression are triggered by
the stimulation of microglial membrane-bound TLR4. To test this
hypothesis, experiments were undertaken to assess tactile and
thermal hypersensitivity in genetically altered (i.e., TLR4 knockout
and point-mutant) mice after L5 nerve transection. In a comple-
mentary study, TLR4 antisense oligodeoxynucleotide (ODN) was
administered intrathecally to L5 spinal nerve injured rats to reduce
the expression of spinal TLR4. Both the genetically altered mice and
the rats treated with TLR4 antisense ODN displayed significantly
attenuated behavioral hypersensitivity and decreased expression
of spinal microglial markers and proinflammatory cytokines as
compared with their respective control groups. This finding shows
that TLR4 contributes to the initiation of CNS neuroimmune acti-
vation after L5 nerve transection. Further understanding of this
early, specific, innate CNSmicroglial response and how it leads
to sustained glialneuronal hypersensitivity may point to new
therapies for the prevention and treatment of neuropathic pain
syndromes.
astrocytes  behavioral hypersensitivity  microglial activation  nerve
injury  neuropathic pain
Neuropathic pain remains a prevalent, persistent, and debil-itating problem. Attempts to elucidate its mechanisms have
focused principally on peripheral nerves, dorsal root ganglion,
and CNS neurons. Recently, however, research has expanded
into the burgeoning field of glialneuronal transmission and
CNS immunologic responses to nerve injury. CNS glia display
immune cell functions in both normal and pathologic conditions,
and there is increasing evidence that neuropathic pain arising
from nerve injury has a CNS neuroimmune component (1, 2).
Spinal glial activation triggers rapid, graded CNS expression of
proinflammatory cytokines (including TNF-, IL-1, and IL-6)
that contributes to the initiation and maintenance of behavioral
hypersensitivity after L5 nerve transection (1, 3, 4). The onset of
proinflammatory cytokine expression correlates with microglial
activation and the initiation of behavioral hypersensitivity (5–8),
and neuroimmune activation in painful neuropathy has been
established (3, 9, 10). However, the mechanistic links between L5
nerve transection, microglial activation, and the genesis of
behavioral hypersensitivity have remained unknown.
Cells of the innate immune system, including monocytes
macrophages, natural killer cells, neutrophils, and microglia
recognize invariant molecular structures of pathogens (termed
pathogen-associated molecular patterns, PAMP) by means of
stable, genetically conserved, pattern-recognition receptors on
the cell surface. The genes producing these receptors are ho-
mologous to the Toll gene in Drosophila and are therefore
termed Toll-like receptors (11). Toll-like receptor 4 (TLR4), the
focus of the present study, is a transmembrane receptor protein
with extracellular leucine-rich repeat domains and a cytoplasmic
signaling domain. TLR4 expression has been demonstrated in
the rodent CNS (12, 13), where in vivo and in vitro studies show
that TLR4 is exclusively expressed by microglia (14, 15). LPS (a
well known exogenous ligand for TLR4) and potential endoge-
nous ligands for TLR4 (e.g., members of the heat shock protein
family and proteoglycans) lead to NF-B activation and subse-
quent induction of proinflammatory cytokines (16, 17). Thus,
there is a plausible linkage of TLR4 to the production of
proinflammatory cytokines, which, in turn, contribute to behav-
ioral hypersensitivity. However, prior research has not conclu-
sively demonstrated a role for TLR4 in the onset of behavioral
hypersensitivity. Our previous results show that increased spinal
microglial TLR4 activation correlates with the onset of behav-
ioral hypersensitivity in rats after injury to the L5 spinal nerve,
even in the absence of exogenous TLR4 ligands such as LPS (18).
The current study was undertaken to determine the mechanistic
contribution of TLR4 and CNS innate immunity to behavioral
hypersensitivity. We postulated that TLR4 responds immediately to
stressors induced by nerve or cell-body damage, including ATP,
heat shock protein, fragments of proteoglycans, and cations.
Our approach to investigating the functional links between
TLR4, microglial activation, and the initiation of behavioral hyper-
sensitivity was twofold. First, we assessed glial activation and
behavioral hypersensitivity after spinal L5 nerve transection in
wild-type mice and in genetically manipulated mice lacking normal
TLR4 expression. Two mouse strains with distinct genetic defects
at the TLR4 loci were used: the TLR4 knockout (KO) mouse
(C57BL10ScNJ), which has a complete deletion of the TLR4 gene
and thus cannot synthesize TLR4 mRNA or protein, and the TLR4
point-mutant mouse (C3HHeJ), which expresses only a mutated
(nonfunctional) TLR4 protein because of an amino acid substitu-
tion at position 712 in the third exon of the TLR4 gene (19, 20).
Second, we assessed glial activation and behavioral hypersensitivity
after L5 nerve transection in normal rats and in rats injected
intrathecally with antisense oligodeoxynucleotide (ODN) to de-
crease CNS expression of TLR4. Both series of experiments
established a role for TLR4 and CNS innate neuroimmune acti-
vation in the onset of behavioral hypersensitivity.
Materials and Methods
Animals. Mice. C57BL10ScNJ mice (TLR4-deleted; n  21) have
a homozygous deletion of 74 kb at the tlr4 locus that removes all
three TLR4 exons (19). C3HHeJ mice (TLR4-deficient; n  8)
possess a dominant-negative point mutation Pro3His at position
712 in the third exon of the TLR4 gene (19). C57BL10ScSnJ (n 
15) and C3HHeN (n  7) mice are the respective wild-type
controls. The C57BL10ScNJ, C57BL10ScSnJ, and C3HHeJ
strains were purchased from The Jackson Laboratory, and the
C3HHeN strain was purchased from Charles River Laboratories.
All mice weighed 25–30 g at the time of surgery.
Abbreviations: TLR4, Toll-like receptor 4; ODN, oligodeoxynucleotide; KO, knockout; GFAP,
glial fibrillary acid protein; COX-2, cyclooxygenase 2.
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Rats. Male Sprague–Dawley rats (n  48) purchased from Harlan
(Indianapolis) were used. All weighed 200–250 g at the time of
surgery.
The Institutional Animal Care and Use Committee at Dart-
mouth College approved all experimental protocols. In accordance
with the guidelines set forth by the International Association for the
Study of Pain, efforts were made throughout to minimize animal
discomfort and to use the fewest animals needed for statistical
significance. Animals were housed on a 12-h light, 12-h dark cycle
with food and water available ad libitum.
Surgery. Animals were anesthetized with halothane in an O2
carrier (induction, 4% and maintenance, 2%). A small incision
to the skin overlaying L5-S1 was made, followed by retraction of
the paravertebral musculature from the vertebral transverse
processes. The L6 transverse process was partially removed,
exposing the L4 and L5 spinal nerves. The L5 spinal nerve was
identified, lifted slightly, and transected. The wound was irri-
gated with saline and closed in two layers with 3-0 polyester
suture (fascial plane) and surgical skin staples.
Behavioral Testing. For mice, mechanical sensitivity was assessed
by applying 0.008- and 0.015-g von Frey filaments (Stoelting,
Wood Dale, IL) on the plantar surface of the ipsilateral hind
paw. For rats, 2- and 12-g von Frey filaments were used. These
stimuli are normally nonnoxious. Allodynia was characterized as
the number of paw withdrawals in three sets of 10 stimulations
each, and was tested on days 1, 3, 5, 7, 10, and 14 after surgery
for mice and on days 1, 3, 5, and 7 for rats. Thermal sensitivity
was determined by using paw-withdrawal latencies to radiant
heat and tail-f lick latencies to tail immersion in hot water (49°C).
Three tail-f lick and paw-withdrawal latencies were obtained per
animal for each testing session. Animals were tested for baseline
responses three times before undergoing the L5 spinal nerve
transection surgery.
Intrathecal Oligodeoxynucleotide Administration. We conducted a
set of experiments by using the L5 spinal nerve transection model
in rats. TLR4 antisense ODN, mismatch ODN, and a random
control oligonucleotide labeled with FITC were custom-made by
Biognostik (Göttingen, Germany). The oligonucleotide was resus-
pended in sterile PBS at a final concentration of 1 gl for
mismatch ODN and 2 gl for antisense ODN. The rats were
divided into three groups based on the final amount of ODN
intrathecally administered. In the first group, rats were adminis-
tered antisense ODN (10 gday; n  8), mismatch ODN (10
gday; n  8), or saline (n  8), and tested separately. In the
second group, rats were administered antisense ODN (20 gday;
n  8), mismatch ODN (20 gday; n  8), or saline (n  8). All
rats in both groups underwent L5 nerve transection surgery, and,
after daily behavioral testing that took place between 8:00 and 10:00
a.m., were administered ODN intrathecally by means of lumbar
puncture under brief inhalational anesthesia for 7 days starting 1
day before surgery. In the third group, 20 g of FITC-labeled
random oligonucleotide was injected intrathecally by means of
lumbar puncture in three rats. These rats were killed at 4, 8, or 12 h
after injection to determine the optimal cellular uptake time of
FITC-labeled oligonucleotide. The injection volume was 10 l
followed by a 15-l sterile PBS wash.
The ODN solutions were aliquoted in sterile 1.5-ml Eppen-
dorf tubes. The aliquots were stored at 20°C, and three aliquots
were taken out daily during the 7 days of intrathecal adminis-
tration. The experimenter was blind to their content throughout
the study. Behavioral testing was carried out 1 h before the
administration of TLR4 antisense ODN, mismatch ODN, or
saline. All rats in groups 1 and 2 were killed on day 7 after
Fig. 1. Mechanical allodynia and thermal hyperalgesia in the L5 spinal nerve-transected mice. Shown are responses measured by foot-lift response frequency
to stimulation with 0.008-g (a) and 0.015-g (b) von Frey filament. Paw-withdrawal latency (c) and tail-flick latency (d) are shown postoperatively. Mechanical
allodynia and thermal hyperalgesia were significantly attenuated in KO mice (C57BL10SCNJ; n  21) and TLR4 mutant mice (C3HHeJ; n  8) relative to their
respective controls, i.e., TLR4 wild-type mice (C57BL10ScSnJ; n  15) and C3HHeN mice (n  7). In a and b, asterisks indicate significant attenuation in tactile
allodynia compared with the wild-type controls (***, P  0.001; two-way ANOVA followed by Bonferroni post hoc test). In c and d, asterisks and  indicate
significant decreases in paw-withdrawal and tail-flick latencies compared with wild type (***, P  0.001; **, P  0.01; *, P  0.05; , P  0.05 vs. ScSnJ, two-way
ANOVA followed by Bonferroni post hoc test). For a and b, results are reported as the mean response frequency from three trials of 10 stimulations each  SEM.
For c and d, the results are reported as the mean latency response time of three stimulations  SEM.








surgery, 1 day after the final intrathecal administration of TLR4
antisense ODN, mismatch ODN, or saline.
Real-Time RT-PCR. To test for a direct link between TLR4 expression,
microglial activation, and proinflammatory cytokine expression, we
used quantitative RT-PCR to measure levels of mRNA for TLR4,
CD11b, CD14, IL-1, IL-6, and TNF- in homogenates from
lumbar spinal cord tissue. The method has been described (18).
Briefly, the animals were killed by carbon dioxide asphyxiation
followed by decapitation on days 3, 7, and 14 after surgery for mice
and on day 7 for rats. The spinal cord tissue was flushed out with
PBS by using a 15-ml syringe and 18-gauge needle. The harvested
cords were immediately snap-frozen to 51°C and stored at 80°C
before RNA isolation. Total RNA was isolated from the L5 lumbar
spinal cord tissue and processed for RT-PCR. The primers and
probes selected for this experiment met the GC content require-
ment and had melting temperatures of 60°C and 70°C, respectively
(see Tables 1 and 2, which are published as supporting information
on the PNAS web site).
Immunohistochemistry. To assess the time course of CD11bCR3
immunoreactivity, a separate group of mice consisting of
C57BL10ScNJ (KO) mice and C57BL10ScSnJ (wild-type)
mice, four injured and two uninjured per strain, was perfused
transcardially with 0.1 M PBS followed by 4% paraformaldehyde
in PBS on days 3, 7, and 14 after surgery. The L5 segment of the
spinal cord was harvested by means of a laminectomy. Immu-
nohistochemistry was performed on transverse 20-m L5 spinal
cord sections by using an avidin-biotin complex technique
previously described (21). A monoclonal antibody for CD11b
was used to label the time-course expression of CD11bCR3 on
activated microglia (1:500 working dilution, Serotec).
Statistical Analysis. The statistical significance of differences be-
tween TLR4 KO, point-mutant, TLR4 antisense ODN-treated, and
control animals was determined by using multivariate two-way
ANOVA followed by post hoc Bonferroni analysis. All statistical
analyses were performed by using PRISM 4.01 (GraphPad, San
Diego). A P value of 0.05 was considered significant.
Results
TLR4 Is Critical for Pain Induction After Nerve Injury. The TLR4 KO
mice (C57BL10SCNJ; n  21) and point-mutant mice (C3HHeJ;
n  8) displayed significantly attenuated mechanical allodynia
compared with their respective wild-type controls (C57BL10
ScSnJ; n  15 and C3HHeN; n  7) for 0.008-g (P  0.001) and
0.015-g (P  0.001) von Frey filament stimulations beginning at day
1 after surgery (Fig. 1 a and b). Fig. 1c shows that TLR4 KO and
point-mutant mice also displayed a significantly attenuated re-
sponse to heat for days 1–7 (P  0.05) and 10–14 after surgery (P 
0.001). Fig. 1d shows that the tail-flick response to immersion in
49°C water was also significantly attenuated for these mice for days
1–7 (P  0.05) and 10–14 after surgery (P  0.001).
Knockout of TLR4 Leads to Attenuation in Spinal Glial Activation. A 3-
to 5-fold decrease in expression of mRNA for CD11b and CD14
Fig. 2. Real-time quantitative RT-PCR analyses of mRNA temporal expression of microglial and astrocytic activation markers in mouse lumbar spinal cord.
TaqMan real-time RT-PCR was performed. Total mRNA was isolated from L5 lumbar spinal cord tissue of KO mice (C57BL10SCNJ) and TLR4 wild-type control
mice (C57BL10ScSnJ). Data are shown for normal, uninjured mice (N; n  3 per strain) or KO mice (n  4) and wild-type mice (n  4) subjected to L5 nerve
transection surgery at days 3, 7, and 14 for CD11b (a), CD14 (b), TLR4 (c) and GFAP (d) in the presence of their respective primers and probes. No PCR amplification
was observed in the TLR4-deficient mice with TLR4 primers and probe (data not shown). (c) The time-course expression of TLR4 in wild-type mice after injury.
The real-time PCR was performed in duplicate for both target gene and GAPDH. The level of gene expression was calculated after normalizing against GAPDH
in each sample and is presented as relative mRNA expression units. Values are mean  SEM. (**, P  0.01 vs. KO; *, P  0.05 vs. KO; two-way ANOVA followed
by Bonferroni post hoc test.)
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was observed in TLR4 KO mice compared with the wild-type
control group beginning at day 3 after surgery (Fig. 2 a and b;
P  0.001). Fig. 2c shows graded, significant up-regulation of
TLR4 mRNA in the wild-type control group (P  0.001). No
TLR4 mRNA was detected in the TLR4 KO mice. Messenger
RNA for the astrocytic activation marker glial fibrillary acid
protein (GFAP) also decreased in TLR4 KO mice relative to the
wild-type control group, starting at day 7 after surgery (Fig. 2d;
P  0.001).
TLR4: Link Between Innate Immunity and Spinal Proinflammatory
Cytokine Expression. Significantly (3- to 5-fold) lower spinal
expression of mRNA for IFN-, IL-1, and TNF- was observed
after injury in the TLR4 KO mice as compared with the
wild-type control group (Fig. 3; P  0.001).
Relationship Between Microglial Activation and TLR4. In injured
wild-type mice, we observed robust immunoreactive staining of
CD11bCR3 throughout the dorsal horn ipsilateral to the L5
nerve transection (laminae I-IV) on days 3, 7, and 14 after
surgery. By contrast, CD11bCR3 immunoreactivity was re-
duced almost to baseline levels in the ipsilateral dorsal horn of
injured TLR4 KO mice (Fig. 4). These immunohistochemical
protein data support the mRNA findings for CD11b (see Fig. 2a).
Spinal TLR4 Antisense ODN-Attenuated Behavioral Hypersensitivity in
Rats. We confirmed that FITC-labeled random control ODN was
incorporated into the spinal cord. Colabeling with DAPI dem-
onstrated the proximity of the FITC-labeled ODN to the nu-
cleus, showing that the modified ODN was incorporated into the
CNS parenchyma (see Fig. 7, which is published as supporting
information on the PNAS web site). Daily intrathecal injection
of 10 g of TLR4 antisense ODN resulted in moderate but
significant attenuation of both mechanical allodynia and thermal
hyperalgesia; more significant attenuation was observed with
20-g daily injections (Fig. 5; P  0.001). Daily injections of
saline or of 10 or 20 g of mismatch ODN did not alter
mechanical or thermal hypersensitivity.
TLR4 Antisense ODN Leads to Decreased Microglial Activation and
Proinflammatory Cytokine Expression. Because of the potential for
TLR4 antisense ODN backbone toxicity, the maximum daily
intrathecal administration of TLR4 antisense ODN was 20 g.
This dosage provided a 56% decrease in spinal TLR4 mRNA
expression, as shown in Fig. 6a (P  0.001). Decreased expres-
sion of TLR4 paralleled the decreased expression of the micro-
glial activation markers CD11b (51%) and CD14 (44%) (P 
0.001). The decrease in TLR4 also led to a significant decrease
in proinflammatory cytokines, i.e., TNF- (17%), IL-6 (52%),
and IL-1 (53%); P  0.001 in all cases in TLR4 antisense
ODN-treated rats as compared with rats treated with saline or
mismatch ODN (Fig. 6b).
Fig. 3. Real-time RT-PCR analyses of the temporal expression of proinflam-
matory cytokine mRNA in mouse lumbar spinal cord. Total mRNA was isolated
from L5 lumbar spinal cord tissue of normal, uninjured mice (N) (n  3 per
strain), TLR4 KO mice (n  4), and wild-type mice (n  4) subjected to L5 nerve
transection surgery at days 3, 7, and 14 for INF- (a), IL-1 (b) and TNF- (c). The
level of gene expression was calculated after normalizing against GAPDH in
each sample and is presented as relative mRNA expression units. Values are
mean  SEM. (***, P  0.001 vs. KO; *, P  0.05 vs. KO; two-way ANOVA
followed by Bonferroni post hoc test.)
Fig. 4. Immunohistochemical staining for CD11bCR3 of microglia in the
ipsilateral L5 lumbar spinal cord dorsal horns 3, 7, and 14 days after surgery.
Shown are representative photomicrographs depict microglial activation by
using CD11bCR3 immunoreactivity in uninjured TLR4 KO and its wild-type
control mice and in L5 nerve transected KO and WT mice at 3, 7, and 14 days
after surgery. Microglial activation in the dorsal horn of the spinal cord
demonstrated a baseline staining in uninjured mice, a mild response at 3, 7,
and 14 days after surgery for KO mice, and a moderate to intense response at
day 3 and an intense response at 7 and 14 days after surgery in WT mice.









The data presented herein demonstrate for the first time, to our
knowledge, a key role for microglial TLR4 in the induction of
behavioral hypersensitivity in rodent models of neuropathy. Our
data also show that the mRNA expression of the microglial
activation markers, TLR4, CD11bCR3, and CD14, were only
elevated at the initiation phase of behavioral hypersensitivity (days
3 and 7). Conversely, the astrocytic activation marker GFAP
showed an opposite pattern with a graded increase in the mRNA
expression level at later time points (days 7 and 14). These results
are consistent with our previous finding that suggests that microglia
are involved in the initiating phase of behavioral hypersensitivity,
whereas astrocytes are involved in the maintenance phase (18, 22).
Many factors have been postulated to activate microglia after
injury, but our finding that microglial TLR4 plays a crucial part as
a receptor in the induction phase of behavioral hypersensitivity in
rodent models of neuropathy may be novel.
After L5 nerve transection injury, mediators are released or
activated, causing secondary swelling and damage to neurons.
Such mediators include: ATP, glutamate, acidosis, free saturated
or unsaturated fatty acids, high-extracellular potassium, seroto-
nin, bradykinin, substance P, histamine, and products from the
cyclooygenase and lipoxygenase pathway of the arachidonic acid
metabolism (23). At the spinal cord level, these alterations lead
to a hyperexcitable state with intense nociceptive input to the
dorsal horn and the chemical sensitization of high-threshold
nociceptors to transmit low-intensity nonnoxious stimuli.
One specific example of a TLR4 ligand released after nerve
injury are saturated fatty acids, which have been shown to induce
the activation of NF-b and the up-regulation of cyclooxygenase 2
(COX-2) and other inflammatory markers upon interacting with
membrane bound TLR4 of monocytemacrophage such as micro-
glia (24, 25). The up-regulation of COX-2 and its contribution to
central sensitization after various types of peripheral nerve injury
has been well established (26–28). It has also been shown that the
induction of NF-b and the up-regulation of COX-2 was inhibited
by dominant-negative TLR4 (25, 29, 30). These previous findings
suggest that the modulation of COX-2 expression by fatty acids via
the TLR4-derived signaling pathways is one potentially important
pathway that links peripheral nerve injury to behavioral hypersen-
sitivity after microglial TLR4 activation.
We used two strategies to investigate the role of TLR4 in the
induction of behavioral hypersensitivity after L5 nerve transec-
tion. First, two strains of genetically altered mice were used to
examine the effects of complete TLR4 gene deletion and of
functionally mutated TLR4 protein, respectively. Second, intra-
thecal injection of antisense ODN in rats was used to examine the
effects of reduced CNSspinal TLR4 expression. We demon-
strated that after L5 nerve transection, functional knockout, or
point mutation of the TLR4 gene in mice (i) significantly
attenuates L5 nerve transection-induced tactile and thermal
hypersensitivity, (ii) reduces spinal microglial activation as as-
sayed by using CD11bCR3 immunoreactivity and expression of
mRNA for microglial activation markers, (iii) reduces expression
of mRNA for spinal proinflammatory cytokine, and (iv) signif-
icantly decreases expression of mRNA for GFAP. These results
agree with the previously observed correlation between micro-
glial and astrocytic activation and the initiation and maintenance
of behavioral hypersensitivity in rats (18, 22). Furthermore, we
have previously shown that expression of mRNA for CD11b
precedes sustained up-regulation of GFAP in the lumbar spinal
cord in a similar neuropathic pain model in rat (18).
Fig. 5. Dose–response relationship after daily intrathecal administration of
TLR4 antisense ODN in L5 spinal nerve-transected rats. The effect of a daily
intrathecal injection of two doses of TLR4 antisense ODN, mismatch ODN, or
saline solution (10 or 20 g per day) on mechanical allodynia (a) and paw-
withdrawal latencies (b) is shown. Thermal and tactile hypersensitivity were
significantly attenuated in a dose-dependent manner compared with saline
and mismatch ODN-treated rats with marked attenuation observed with
10-g daily injections of TLR4 antisense ODN starting at days 3–7 (P  0.05 and
P  0.01) and day 1 (*, P  0.05), day 3 (**, P  0.01), and through day 7 (***,
P  0.001) for 20-g daily injection of TLR4 antisense ODN (two-way ANOVA
followed by Bonferroni post hoc test).
Fig. 6. Effect of TLR4 antisense ODN on microglial activation and proinflam-
matory cytokine mRNA expression. A daily dose of 20 g of TLR4 antisense
ODN, mismatch ODN, or saline was injected intrathecally for 8 days, starting
1 day before L5 spinal nerve transection. The rats were killed on day 7 after
surgery, and the lumbar spinal cord was processed for RT-PCR. RT-PCR re-
vealed a significant down-regulation of TLR4 (P  0.001). The down-
regulation of TLR4 paralleled a significant decrease in the expression of two
microglial activation markers, CD14 (***, P  0.001) and CD11b (*** P  0.001)
(a), and in that of proinflammatory cytokines TNF-, IL-6, and IL-1 (***, P 
0.001) (b). The level of gene expression was presented as a fold decrease
relative to saline treated rats. Values were mean  SEM. (n  8 per treatment
group; ***, P  0.001; two-way ANOVA followed by Bonferroni post hoc test.)
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We have also shown that TLR4 antisense ODN intrathecally
administered in rats (i) produces a significant and dose-related
attenuation of L5 nerve transection-induced tactile and thermal
hypersensitivity, (ii) reduces expression of mRNA for microglial
markers, and (iii) reduces expression of mRNA for spinal
proinflammatory cytokine.
It is important to note, however, that neither set of experi-
ments in this study completely reversed L5 nerve transection-
induced behavioral hypersensitivity. This finding suggests a
potential role for other glial receptors or glial mediators such as
CD14MD-2, CD11bCR3, or unique glialneuronal signals like
fractalkine in the initiation of behavioral hypersensitivity (31,
32). Thus, our results underscore the complexity of CNS cas-
cades and mediators that may underlie neuronal sensitization,
the pathological correlate to chronic pain.
The involvement of TLR4 in the CNS innate immune response
is now well established (12, 14). Previous studies by our laboratory
and others have shown that TLR4 is mainly expressed by microglia
(14, 15) and that TLR4 participates in the innate immune response
after CNS exposure to LPS (2, 14, 15, 33). Importantly, we have
previously shown that spinal mRNA for TLR4 is increased after L5
nerve transection in the absence of LPS (18, 22). These data,
together with the results presented herein, provide information
related to a component of a mechanistic link between microglial
activation and behavioral hypersensitivity.
The CNS innate immune response includes rapid activation of
immune effectors cells and the release of proinflammatory cyto-
kines such as TNF-, IL-1, and IFN- through the activation of
TLR4 MyD88-dependent or -independent pathways (34). Further-
more, the expression of proinflammatory cytokines by activated
glia after L5 nerve transection has also been shown to be a major
factor contributing to the establishment of behavioral hypersensi-
tivity (4). Given that the knockout or knockdown of TLR4 expres-
sion leads (as shown in the present study) to attenuation of
behavioral hypersensitivity, decreased glial activation, and de-
creased expression of proinflammatory cytokines, our picture of
this aspect of the etiology of behavioral hypersensitivity is signifi-
cantly clarified. Microglial activation occurs through TLR4 and
leads to the enhanced expression of spinal proinflammatory cyto-
kines. Cytokines, in turn, whether alone or by inducing the expres-
sion of known algesic mediators such as substance P, nitric oxide,
nerve growth factor, glutamate, and prostaglandins, produce cen-
tral sensitization (i.e., enhanced excitation and responsiveness of
spinal neurons due to activity-dependent changes in those neurons),
a prerequisite for behavioral hypersensitivity.
That TLR4 provides a mechanistic link between microglial
activation, innate immunity, and the initiation of behavioral hyper-
sensitivity is further supported by previous data from our labora-
tory. In this previous study, when given before (preemptively) to L5
nerve transection, the specific microglial inhibitor minocycline,
resulted in decreased expression of mRNA for microglial activation
markers, including ITGAM (CD11bCR3) and TLR4 mRNA for
proinflammatory cytokines and in the attenuation of behavioral
hypersensitivity (22). Recent work has shown direct involvement of
TLR4 in the expression of costimulatory molecules, MHC class II,
chemokines, integrins, and adhesion molecules, all of which con-
tribute to central sensitization, and thus, to behavioral hypersensi-
tivity (31, 32, 35–41). The present study has also demonstrated that
a decrease of TLR4 leads to a decrease in CD11bCR3 and in
proinflammatory cytokine expression. That is, TLR4 is a microglial
sensor that triggers glial activation and the dynamic CNS immune
response that ensues in response to L5 nerve transection. This
finding agrees with previous studies showing that a deficiency in
CD11bCR3 seriously compromises innate immunity through a
syndrome clinically known as leukocyte adhesion deficiency. This
syndrome provides compelling evidence for the importance of
2-integrins, including CD11bCR3, in mediating leukocyte adhe-
sive, migratory, and phagocytic activities in response to inflamma-
tory stimuli, and underlines their role in facilitating first-line host
defense (42–44).
All these findings support a CNS role for TLR4 and innate
immunity in the etiology of neuropathic pain. The ability of
TLR4 to activate a pathway leading to central sensitization and
nerve injury-induced behavioral hypersensitivity may provide an
opportunity for regulating glial activation, and thus, alleviating
chronic pain due to nerve damage.
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